The product is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G.
<0.001 EU per 1 μg of the peptide by the LAL method
Equine Botulinum Neurotoxin G Immune FAB2
The product is indicted for use in documented or suspected exposure to botulinum toxin serotype G in adults and pediatric patients.
Examples of Clinical Use:
The product binds to botulinum toxin serotype G to prevent toxicity.
Mechanism of action:
Equine Botulinum Neurotoxin G Immune FAB2 is a mix of polyclonal antibodies for botulinum toxin type G. It binds to the toxin with high-affinity and prevents binding to ganglioside anchorage sites and membrane-bound receptors on cholinergic nerve terminals. This prevents internalization of the toxin into the cell and ultimately prevents it from exerting its toxic effects. Due to the long-lasting effects of botulinum toxin, the antibodies must be administered before symptoms present to prevent toxicity.
1. An introduction to Equine Botulinum Neurotoxin G Immune FAB2
Equine Botulinum Neurotoxin G Immune FAB2 is a specialized antibody-based treatment used in the management of botulism. Botulism is a severe and potentially life-threatening condition caused by the neurotoxins produced by certain strains of the bacterium Clostridium botulinum. Equine Botulinum Neurotoxin G Immune FAB2 is derived from horses immunized with a specific variant of the botulinum neurotoxin, known as type G. The immune Fab2 component of the medication is a fragment of the antibody molecule that specifically targets and neutralizes the botulinum neurotoxin G. This treatment works by binding to the botulinum neurotoxin G and preventing it from interacting with nerve cells, thereby blocking its harmful effects. By neutralizing the toxin, Equine Botulinum Neurotoxin G Immune FAB2 can alleviate symptoms and improve outcomes in individuals affected by botulism. Equine Botulinum Neurotoxin G Immune FAB2 is typically administered intravenously and is most commonly used in cases of wound botulism, which occurs when the bacteria invade a wound and produce the neurotoxin. It can also be used in other forms of botulism, such as infant botulism (caused by ingesting spores in contaminated food or honey) or iatrogenic botulism (caused by medical procedures using contaminated material).
2. The composition and structure of Equine Botulinum Neurotoxin G Immune FAB2
Equine Botulinum Neurotoxin G Immune FAB2 is a medication composed of antibodies derived from horses that have been immunized with the specific variant of the botulinum neurotoxin known as type G. The antibodies are purified and formulated into a therapeutic product. The structure of Equine Botulinum Neurotoxin G Immune FAB2 is based on the antibody molecule, which is a Y-shaped protein. Antibodies are part of the immune system and are produced by B-cells in response to an infection or vaccination. They have a unique ability to recognize and bind to specific molecules, in this case, the botulinum neurotoxin G. The immune Fab2 component of Equine Botulinum Neurotoxin G Immune FAB2 is a specific fragment of the antibody molecule. It consists of two Fab (fragment antigen-binding) portions that are responsible for binding to the neurotoxin. Each Fab portion contains a variable region that recognizes and binds to the neurotoxin and a constant region that provides stability and interacts with other components of the immune system. The Fab fragments in Equine Botulinum Neurotoxin G Immune FAB2 have been selected specifically for their ability to neutralize the botulinum neurotoxin G. When administered, the Fab fragments bind to the neurotoxin, preventing it from interacting with nerve cells and inhibiting its toxic effects. Overall, Equine Botulinum Neurotoxin G Immune FAB2 is a preparation of horse-derived antibodies that target and neutralize the botulinum neurotoxin G, providing therapeutic benefits in the management of botulism.
3. Clinical effects of Equine Botulinum Neurotoxin G Immune FAB2
Equine Botulinum Neurotoxin G Immune FAB2, or equine antitoxin, is primarily used as a treatment for botulism caused by botulinum neurotoxin type G. Here are the clinical effects associated with its use: 1. Neutralization of neurotoxin: Equine Botulinum Neurotoxin G Immune FAB2 works by binding to the botulinum neurotoxin G and neutralizing its toxic effects. This prevents further damage to nerve cells and reduces the severity and progression of botulism symptoms. 2. Symptom relief: By neutralizing the toxin, Equine Botulinum Neurotoxin G Immune FAB2 can help alleviate the symptoms of botulism. These symptoms may include muscle weakness, paralysis, difficulty swallowing, droopy eyelids, and respiratory distress. Treatment with equine antitoxin can improve muscle function and respiratory function, making it easier for the patient to breathe and regain strength. 3. Prevention of further complications: Equine Botulinum Neurotoxin G Immune FAB2 administration can also help prevent the development of further complications associated with botulism. These may include aspiration pneumonia due to weakened swallowing muscles, urinary tract infections, or other secondary infections. 4. Decreased hospitalization time: By providing targeted treatment against botulinum neurotoxin G, the use of Equine Botulinum Neurotoxin G Immune FAB2 can potentially reduce the length of hospital stays for patients with botulism. This can help speed up recovery and reduce healthcare costs. 5. Potential allergic reactions: Although rare, there is a risk of hypersensitivity or allergic reactions to equine antitoxin. Patients should be monitored closely during and after administration for any signs of an allergic response, such as rash, itching, difficulty breathing, or swelling. Prompt medical intervention should be provided if any adverse reactions occur. It is important to note that while Equine Botulinum Neurotoxin G Immune FAB2 can be an effective treatment for botulism caused by type G toxin, it does not provide protection against other types of botulinum neurotoxins. The specific clinical effects and outcomes may vary depending on the individual and the severity of the botulism infection. Treatment should always be administered under the supervision of a healthcare professional.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.